Cognition Therapeutics Inc. (CGTX) intrinsic value & 10-year financials
Cognition Therapeutics Inc. (CGTX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.73
- Market cap
- $53.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 1896.6%
- Free cash flow (FY2025)
- —
CGTX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$23.5M | -$0.32 | — | — | 1157.2% |
| FY2024 | — | -$34.0M | -$0.86 | -$28.5M | — | 995.2% |
| FY2023 | — | -$25.8M | -$0.86 | -$16.2M | — | 1829.2% |
| FY2022 | — | -$21.4M | -$0.91 | -$18.7M | — | 7047.1% |
| FY2021 | — | -$11.7M | -$3.13 | -$3.7M | — | 338.2% |
| FY2020 | — | -$7.8M | -$2.38 | -$3.4M | — | 12.4% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
COGNITION THERAPEUTICS INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
COGNITION THERAPEUTICS INC has earned high returns on invested capital, averaging 27.6% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
COGNITION THERAPEUTICS INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
COGNITION THERAPEUTICS INC is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.